Structural analysis of Clostridium botulinum neurotoxin type D as a platform for the development of targeted secretion inhibitors

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Masuyer, Geoffrey ^a,c   Davies, Jonathan R ^a   Moore, Kevin ^b   Chaddock, John A ^b   Acharya, K Ravi ^a  

^a University of Bath   (United Kingdom)

^b IPSEN   (France)

^c STOCKHOLM UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN; BOTULINUM TOXIN TYPE D; HORMONE RECEPTOR; NEUROPEPTIDE RECEPTOR; RECOMBINANT PROTEIN; SOMATOTROPIN RELEASING HORMONE RECEPTOR;

ANIMAL; BIOSYNTHESIS; CHEMISTRY; CHO CELL LINE; CLASSIFICATION; CLOSTRIDIUM BOTULINUM; CRICETULUS; GENETICS; HAMSTER; HUMAN; ISOLATION AND PURIFICATION; METABOLISM; PROTEIN TERTIARY STRUCTURE; SEROTYPE; SMALL ANGLE SCATTERING; X RAY CRYSTALLOGRAPHY; X RAY DIFFRACTION;

ANIMALS; BOTULINUM TOXINS; CHO CELLS; CLOSTRIDIUM BOTULINUM; CRICETINAE; CRICETULUS; CRYSTALLOGRAPHY, X-RAY; HUMANS; PROTEIN STRUCTURE, TERTIARY; RECEPTORS, NEUROPEPTIDE; RECEPTORS, PITUITARY HORMONE-REGULATING HORMONE; RECOMBINANT PROTEINS; SCATTERING, SMALL ANGLE; SEROGROUP; X-RAY DIFFRACTION;

EID: 84940885067     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep13397     Document Type: Article

References (45)

1. Schiavo, G., Matteoli, M. & Montecucco, C. Neurotoxins affecting neuroexocytosis. Physiol. Rev. 80, 717-766 (2000).
2. Chen, S. Clinical uses of botulinum neurotoxins: current indications, limitations and future developments. Toxins (Basel) 4, 913-939 (2012).
3. Montal, M. Botulinum neurotoxin: a marvel of protein design. Annu. Rev. Biochem. 79, 591-617 (2010).
4. Südhof, T. C. & Rothman, J. E. Membrane fusion: grappling with SNARE and SM proteins. Science 323, 474-477 (2009).
5. Steinman, A., Galon, N., Arazi, A., Bar-Giora, Y. & Shpigel, N. Y. Cattle immune response to botulinum type D toxoid: results of a vaccination study. Vaccine 25, 7636-40 (2007).
6. Coffield, J. A. et al. In vitro characterization of botulinum toxin types A, C and D action on human tissues: combined electrophysiologic, pharmacologic and molecular biologic approaches. J. Pharmacol. Exp. Ther. 280, 1489-1498 (1997).
7. Eleopra, R. et al. Botulinum neurotoxin serotype D is poorly effective in humans: an in vivo electrophysiological study. Clin. Neurophysiol. 124, 999-1004 (2013).
8. Kroken, A. R., Karalewitz, A. P.-A., Fu, Z., Kim, J.-J. P. & Barbieri, J. T. Novel ganglioside-mediated entry of botulinum neurotoxin serotype D into neurons. J. Biol. Chem. 286, 26828-26837 (2011).
9. Peng, L., Tepp, W. H., Johnson, E. A. & Dong, M. Botulinum neurotoxin D uses synaptic vesicle protein SV2 and gangliosides as receptors. PLoS Pathog. 7, e1002008 (2011).
10. Schiavo, G. et al. Identification of the nerve terminal targets of botulinum neurotoxin serotypes A, D, and E. J. Biol. Chem. 268, 23784-23787 (1993).
11. Naumann, M., Boo, L. M., Ackerman, A. H. & Gallagher, C. J. Immunogenicity of botulinum toxins. J. Neural. Transm. 120, 275-290 (2013).
12. Masuyer, G., Chaddock, J. A., Foster, K. A. & Acharya, K. R. Engineered botulinum neurotoxins as new therapeutics. Annu. Rev. Pharmacol. Toxicol. 54, 27-51 (2014).
13. Somm, E. et al. A botulinum toxin-derived targeted secretion inhibitor downregulates the GH/IGF1 axis. J. Clin. Invest. 122, 3295-3306 (2012).
14. Leggett, J. et al. GHRH receptor-targeted botulinum neurotoxin selectively inhibits pulsatile GH secretion in male rats. Endocrinology 154, 3305-3318 (2013).
15. Somm, E. et al. Comparative inhibition of the GH/IGF-I axis obtained with either the targeted secretion inhibitor SXN101959 or the somatostatin analog octreotide in growing male rats. Endocrinology 154, 4237-4248 (2013).
16. Foster, K. A. et al. Re-engineering the target specificity of Clostridial neurotoxins-A route to novel therapeutics. Neurotox. Res. 9, 101-7 (2006).
17. Masuyer, G. et al. Crystal structure of a catalytically active, non-toxic endopeptidase derivative of Clostridium botulinum toxin A. Biochem. Biophys. Res. Commun. 381, 50-53 (2009).
18. Masuyer, G., Beard, M., Cadd, V. A., Chaddock, J. A. & Acharya, K. R. Structure and activity of a functional derivative of Clostridium botulinum neurotoxin B. J. Struct. Biol. 174, 52-57 (2011).
19. Lacy, D. B., Tepp, W., Cohen, A. C., DasGupta, B. R. & Stevens, R. C. Crystal structure of botulinum neurotoxin type A and implications for toxicity. Nat. Struct. Biol. 5, 898-902 (1998).
20. Swaminathan, S. & Eswaramoorthy, S. Structural analysis of the catalytic and binding sites of Clostridium botulinum neurotoxin B. Nat. Struct. Biol. 7, 693-699 (2000).
21. Kumaran, D. et al. Domain organization in Clostridium botulinum neurotoxin type E is unique: its implication in faster translocation. J. Mol. Biol. 386, 233-245 (2009).
22. Krissinel, E. & Henrick, K. Inference of macromolecular assemblies from crystalline state. J. Mol. Biol. 372, 774-797 (2007).
23. Arndt, J. W., Chai, Q., Christian, T. & Stevens, R. C. Structure of botulinum neurotoxin type D light chain at 1.65A resolution: repercussions for VAMP-2 substrate specificity. Biochemistry 45, 3255-3262 (2006).
24. Guo, J. & Chen, S. Unique substrate recognition mechanism of the botulinum neurotoxin D light chain. J. Biol. Chem. 288, 27881-27887 (2013).
25. Agarwal, R., Schmidt, J. J., Stafford, R. G. & Swaminathan, S. Mode of VAMP substrate recognition and inhibition of Clostridium botulinum neurotoxin F. Nat. Struct. Mol. Biol. 16, 789-794 (2009).
26. Breidenbach, M. A. & Brunger, A. T. Substrate recognition strategy for botulinum neurotoxin serotype A. Nature 432, 925-929 (2004).
27. Brünger, A. T. et al. Botulinum neurotoxin heavy chain belt as an intramolecular chaperone for the light chain. PLoS Pathog. 3, 1191-1194 (2007).
28. Sikorra, S., Henke, T., Galli, T. & Binz, T. Substrate recognition mechanism of VAMP/synaptobrevin-cleaving clostridial neurotoxins. J. Biol. Chem. 283, 21145-21152 (2008).
29. Galloux, M. et al. Membrane Interaction of botulinum neurotoxin A translocation (T) domain. The belt region is a regulatory loop for membrane interaction. J. Biol. Chem. 283, 27668-27676 (2008).
30. Barabutis, N. & Schally, A. V. Growth hormone-releasing hormone: extrapituitary effects in physiology and pathology. Cell Cycle 9, 4110-4116 (2010).
31. Svergun, D., Barberato, C. & Koch, M. H. J. Crysol-A program to evaluate X-ray solution scattering of biological macromolecules from atomic coordinates. J. Appl. Cryst. 28, 768-773 (1995).
32. Gildea, R. J. et al. New methods for indexing multi-lattice diffraction data. Acta Crystallogr. D70, 2652-2666 (2014).
33. Evans, P. Scaling and assessment of data quality. Acta Crystallogr. D62, 72-82 (2006).
34. Collaborative Computational Project, Number 4. The CCP4 suite: programs for protein crystallography. Acta. Crystallogr. D50, 760-3 (1994).
35. Evans, P. & Murshudov, G. N. How good are my data and what is the resolution? Acta Crystallogr. D69, 1204-1214 (2013).
36. McCoy, A. J. et al. Phaser crystallographic software. J. Appl. Crystallogr. 40, 658-674 (2007).
37. Cowtan, K. Fitting molecular fragments into electron density. Acta Crystallogr. D64, 83-89 (2008).
38. Murshudov, G. N. et al. Refmac5 for the refinement of macromolecular crystal structures. Acta Crystallogr. D67, 355-67 (2011).
39. Emsley, P., Lohkamp, B., Scott, W. G. & Cowtan, K. Features and development of Coot. Acta Crystallogr. D66, 486-501 (2010).
40. Chen, V. B. et al. MolProbity: all-Atom structure validation for macromolecular crystallography. Acta Crystallogr. D66, 12-21 (2010).
41. Blanchet, C. E. et al. Instrumental setup for high-throughput small-And wide-Angle solution scattering at the X33 beamline of EMBL Hamburg. J. Appl. Cryst. 45, 489-495 (2012).
42. Konarev, P. V., Volkov, V. V., Sokolova, A. V., Koch, M. H. J. & Svergun, D. I. PRIMUS: a Windows PC-based system for smallangle scattering data analysis. J. Appl. Cryst. 36, 1277-1282 (2003).
43. Svergun, D. I. Determination of the regularization parameter in indirect-transform methods using perceptual criteria. J. Appl. Cryst. 25, 495-503 (1992).
44. Franke, D. & Svergun, D. I. Dammif, a program for rapid ab-initio shape determination in small-Angle scattering. J. Appl. Cryst. 42, 342-346 (2009).
45. Volkov, V. V. & Svergun, D. I. Uniqueness of ab initio shape determination in small-Angle scattering. J. Appl. Cryst. 36, 860-864 (2003).